FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures

The FDA plans to review easing restrictions on seven peptides, including BPC-157 and TB-500, amid pressure from Health Secretary Robert F. Kennedy Jr. and his allies. Critics warn that unregulated peptide use poses significant safety risks, as these substances lack clinical testing and FDA approval.